



Session Coordinator

Policy & Regulatory Affairs Council

Health Technology Assessment (HTA) Project Group

Neuroimaging Committee

EU Affairs Track

Sunday, October 18, 13:30-14:15

Session Title

Amyloid PET in Europe: From Evidence to Access

Co-Chairs

Prof. Dr. **Igor Yakushev**, EANM Neuroimaging Committee, Department of Nuclear Medicine, School of Medicine, Technical University of Munich (Germany)

Prof. Dr. **Nadia Withofs**, EANM HTA project group, University hospital of Liege, ULiege (Belgium)

Programme

13:30-13:50 (20 min.)	Evidence Generation for Amyloid PET: registries, Real-world Data, and Clinical Utility in Europe Prof. Dr. Alexander Drzezga, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany
13:50-14:05 (15 min.)	The Economic Argument: Health Technology Assessment (HTA) and Cost-Effectiveness of Amyloid PET Dr. Sebastian Vermeersch, Senior Manager, Hict (Healthcare Consulting & Health Economics), Ghent, Belgium
14:05-14:15 (10 min.)	Panel discussion: What is Needed for Equitable and Sustainable Access to Amyloid PET in Europe? - Panel discussion - Q&A with the audience - Concluding remarks by the moderators

Summary

This joint NIC-HTA Project Group session looks at how evidence on amyloid PET informs reimbursement and coverage decisions in Europe. Using the experience of [18F]FDG PET as a reference, the session will explore the current heterogeneity in access, utilization, and reimbursement of PET imaging across Europe and discuss implications for the implementation of amyloid PET. It discusses how HTA bodies and payers assess value and where evidence gaps remain for imaging technologies. The session places amyloid PET in the context of evolving EU HTA and national decision-making, concluding with key policy takeaways for patient access.